CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 127 enrolled
Drug / intervention
Lenvatinibdrug
Likely dose
Lenvatinib 14 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04447755
NCT04447755Phase 2Completed
CompareCT.gov

An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Malignancies

Merck Sharp & Dohme LLC·interventional·Posted Jun 25, 2020·Updated Oct 3, 2025

In Brief

A Phase 2 clinical trial evaluating Lenvatinib for Relapsed or Refractory Solid Tumors. Completed, enrolled 127 participants across 49 sites in 20 countries.

Detailed Summary

The main purpose of this study is to evaluate the antitumor activity and safety of lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration. Participants were enrolled into Ewing sarcoma (EWS), rhabdomyosarcoma (RMS), high-grade glioma (HGG), diffuse midline glioma, medulloblastoma, ependymoma, and Other Solid Tumors Excluding Osteosarcoma, diffuse midline glioma, medulloblastoma, and ependymoma cohorts.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed or Refractory Solid Tumors
CountriesArgentina, Australia, Belgium, Croatia, Czechia, France, Guatemala, Hungary, Israel, Italy, New Zealand, Peru, Russia, Serbia, South Africa, South Korea, Spain, Sweden, Turkey (Türkiye), United States
CollaboratorsEisai Inc.

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJun 25, 2020
Enrollment StartJul 30, 2020
Primary CompletionSep 16, 2022
Study CompletionFeb 13, 2025
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.0 years ago

Interventions

Lenvatinibdrug

Lenvatinib capsules administered orally at 14 mg/m\^2 QD